Astria Therapeutics (ATXS) Financials

$5.36 +0.20 (+3.88%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$5.34 -0.02 (-0.28%)

As of 05/2/2025 04:41 PM Eastern

Annual Income Statements for Astria Therapeutics

This table shows Astria Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-52	-73	-94
Consolidated Net Income / (Loss)	-52	-73	-94
Net Income / (Loss) Continuing Operations	-52	-73	-94
Total Pre-Tax Income	-52	-73	-94
Total Operating Income	-54	-83	-112
Total Gross Profit	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	54	83	112
Selling, General & Admin Expense	19	26	34
Research & Development Expense	34	57	77
Total Other Income / (Expense), net	1.67	10	17
Interest & Investment Income	1.72	10	17
Other Income / (Expense), net	-0.06	-0.06	-0.06
Basic Earnings per Share	($3.55)	($2.42)	($1.68)
Weighted Average Basic Shares Outstanding	14.62M	30.12M	56.16M
Diluted Earnings per Share	($3.55)	($2.42)	($1.68)
Weighted Average Diluted Shares Outstanding	14.62M	30.12M	56.16M
Weighted Average Basic & Diluted Shares Outstanding	27.99M	54.90M	56.43M

This table shows Astria Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-12	-	-11	-13	-18	-31	-20	-24	-25	-26
Consolidated Net Income / (Loss)	-12	-	-11	-13	-18	-31	-20	-24	-25	-26
Net Income / (Loss) Continuing Operations	-12	-	-11	-13	-18	-31	-20	-24	-25	-26
Total Pre-Tax Income	-12	-	-11	-13	-18	-31	-20	-24	-25	-26
Total Operating Income	-12	-	-13	-15	-20	-34	-24	-29	-29	-30
Total Operating Expenses	12	-	13	15	20	34	24	29	29	30
Selling, General & Admin Expense	4.69	-	5.46	6.01	6.90	7.33	8.42	8.09	8.50	9.43
Research & Development Expense	7.70	-	8.03	9.09	13	27	16	21	21	20
Total Other Income / (Expense), net	0.39	-	2.31	2.54	2.51	2.79	4.22	4.63	4.48	3.97
Interest & Investment Income	0.44	-	2.32	2.56	2.53	2.80	4.24	4.65	4.52	3.96
Other Income / (Expense), net	-0.05	-	-0.02	-0.02	-0.02	-0.01	-0.02	-0.02	-0.04	0.01
Basic Earnings per Share	($0.87)	-	($0.40)	($0.45)	($0.63)	($0.94)	($0.38)	($0.43)	($0.42)	($0.45)
Weighted Average Basic Shares Outstanding	13.74M	14.62M	27.94M	28.02M	28.04M	30.12M	52.29M	56.49M	57.82M	56.16M
Diluted Earnings per Share	($0.87)	-	($0.40)	($0.45)	($0.63)	($0.94)	($0.38)	($0.43)	($0.42)	($0.45)
Weighted Average Diluted Shares Outstanding	13.74M	14.62M	27.94M	28.02M	28.04M	30.12M	52.29M	56.49M	57.82M	56.16M
Weighted Average Basic & Diluted Shares Outstanding	16.83M	27.99M	28.03M	-	36.30M	54.90M	54.91M	112.85M	56.43M	56.43M

This table details how cash moves in and out of Astria Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-66	155	-116
Net Cash From Operating Activities	-44	-68	-81
Net Cash From Continuing Operating Activities	-44	-68	-81
Net Income / (Loss) Continuing Operations	-52	-73	-94
Consolidated Net Income / (Loss)	-52	-73	-94
Amortization Expense	-	-0.09	-5.61
Non-Cash Adjustments To Reconcile Net Income	6.23	6.34	13
Changes in Operating Assets and Liabilities, net	2.07	-1.80	5.27
Net Cash From Investing Activities	-167	135	-192
Net Cash From Continuing Investing Activities	-167	135	-192
Purchase of Property, Plant & Equipment	-0.09	-0.03	-0.33
Purchase of Investments	-396	-1,924	-4,245
Sale and/or Maturity of Investments	229	2,060	4,053
Net Cash From Financing Activities	145	88	157
Net Cash From Continuing Financing Activities	145	88	157
Issuance of Debt	-	28	35
Issuance of Common Equity	145	59	117
Other Financing Activities, net	0.08	0.42	4.79

This table details how cash moves in and out of Astria Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	16	-25	182	-68	-14	56	-3.52	-85	-6.48	-21
Net Cash From Operating Activities	-10	-11	-13	-11	-14	-30	-19	-17	-28	-17
Net Cash From Continuing Operating Activities	-10	-11	-13	-11	-14	-30	-19	-17	-28	-17
Net Income / (Loss) Continuing Operations	-12	-13	-11	-13	-18	-31	-20	-24	-25	-26
Consolidated Net Income / (Loss)	-12	-13	-11	-13	-18	-31	-20	-24	-25	-26
Amortization Expense	-	-	-	-	-	-	-	-	-1.73	-1.38
Non-Cash Adjustments To Reconcile Net Income	1.26	1.05	1.19	1.37	1.70	2.07	2.08	4.26	3.63	3.41
Changes in Operating Assets and Liabilities, net	0.49	1.55	-3.26	0.58	1.77	-0.90	-1.25	5.63	-5.33	6.23
Net Cash From Investing Activities	1.95	-135	195	-58	-0.00	-2.02	-126	-68	6.19	-3.72
Net Cash From Continuing Investing Activities	1.95	-135	195	-58	-0.00	-2.02	-126	-68	6.19	-3.72
Purchase of Investments	-53	-179	-96	-207	-914	-708	-1,049	-1,388	-1,059	-749
Sale and/or Maturity of Investments	55	43	291	149	914	706	923	1,320	1,065	745

This table presents Astria Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	231	255	342
Total Current Assets	228	251	335
Cash & Equivalents	21	176	60
Short-Term Investments	206	71	268
Prepaid Expenses	1.25	4.41	6.51
Plant, Property, & Equipment, net	0.00	0.00	0.00
Total Noncurrent Assets	2.94	3.72	7.72
Other Noncurrent Operating Assets	2.94	3.72	7.72
Total Liabilities & Shareholders' Equity	231	255	342
Total Liabilities	9.42	12	23
Total Current Liabilities	9.06	12	19
Accounts Payable	0.79	1.51	4.32
Accrued Expenses	7.69	9.71	13
Other Current Liabilities	0.58	0.33	1.38
Total Noncurrent Liabilities	0.36	0.00	3.97
Other Noncurrent Operating Liabilities	0.36	0.00	3.97
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	221	243	319
Total Preferred & Common Equity	221	243	319
Preferred Stock	96	95	95
Total Common Equity	125	148	224
Common Stock	633	728	899
Retained Earnings	-508	-581	-675
Accumulated Other Comprehensive Income / (Loss)	-0.08	0.00	0.16

This table presents Astria Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	120	218	207	194	379	368	362
Total Current Assets	118	215	204	191	375	358	352
Cash & Equivalents	46	202	134	120	172	87	81
Short-Term Investments	71	11	69	69	198	267	263
Prepaid Expenses	1.91	2.12	1.46	2.66	4.61	3.19	7.58
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Noncurrent Assets	1.33	2.80	2.64	2.40	4.29	10	9.78
Other Noncurrent Operating Assets	1.33	2.80	2.64	2.40	4.29	10	9.78
Total Liabilities & Shareholders' Equity	120	218	207	194	379	368	362
Total Liabilities	6.95	6.88	6.65	9.38	11	21	20
Total Current Liabilities	6.44	6.67	6.60	9.38	11	16	16
Accounts Payable	0.79	0.93	0.83	1.14	0.86	2.34	1.28
Accrued Expenses	5.07	5.16	5.18	7.76	10	13	13
Other Current Liabilities	0.58	0.59	0.59	0.49	0.17	1.25	1.38
Total Noncurrent Liabilities	0.50	0.21	0.05	0.00	0.00	4.54	4.26
Other Noncurrent Operating Liabilities	0.50	0.21	0.05	0.00	-	4.54	4.26
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	113	211	200	184	368	347	342
Total Preferred & Common Equity	113	211	200	184	368	347	342
Preferred Stock	96	95	95	95	95	95	95
Total Common Equity	16	116	105	89	272	252	246
Common Stock	511	635	636	638	873	876	895
Retained Earnings	-494	-519	-531	-549	-600	-625	-649
Accumulated Other Comprehensive Income / (Loss)	-0.22	-0.00	0.00	0.00	-0.01	-0.05	0.33

This table displays calculated financial ratios and metrics derived from Astria Therapeutics' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	0.00%
EBITDA Growth	72.54%	-55.30%	-40.94%
EBIT Growth	72.54%	-55.14%	-34.33%
NOPAT Growth	72.56%	-55.19%	-34.36%
Net Income Growth	73.41%	-40.62%	-29.32%
EPS Growth	85.56%	31.83%	30.58%
Operating Cash Flow Growth	-44.38%	-57.23%	-18.65%
Free Cash Flow Firm Growth	74.24%	-69.15%	-21.20%
Invested Capital Growth	-63.31%	34.61%	-159.78%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	-31.78%	-0.85%
EBIT Q/Q Growth	0.00%	-31.64%	3.98%
NOPAT Q/Q Growth	0.00%	-31.54%	3.97%
Net Income Q/Q Growth	0.00%	-33.15%	5.78%
EPS Q/Q Growth	0.00%	-24.10%	22.58%
Operating Cash Flow Q/Q Growth	-11.18%	-40.05%	13.69%
Free Cash Flow Firm Q/Q Growth	0.00%	-37.59%	12.50%
Invested Capital Q/Q Growth	0.00%	21.10%	-237.35%
Profitability Metrics	-	-	-
Gross Margin	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	200.00%	100.00%
Interest Burden Percent	96.78%	175.45%	84.45%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-30.18%	-31.40%	-33.52%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-13.24%	-18.43%	-22.16%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-29.98%	-29.52%
Net Operating Profit after Tax (NOPAT)	-37	-58	-78
NOPAT Margin	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-8.17%	-6.25%	-5.63%
Return On Investment Capital (ROIC_SIMPLE)	-	-23.91%	-24.46%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-54	-83	-112
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-54	-83	-117
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.74	1.57	2.24
Price to Tangible Book Value (P/TBV)	1.74	1.57	2.24
Price to Revenue (P/Rev)	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.02	-1.02	-1.02
Leverage Ratio	1.04	2.09	1.06
Compound Leverage Factor	1.01	1.83	0.90
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	43.58%	78.42%	29.86%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	56.42%	60.79%	70.14%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	11.16	17.76	10.31
Noncontrolling Interest Sharing Ratio	56.12%	41.29%	33.90%
Liquidity Ratios	-	-	-
Current Ratio	25.13	21.73	17.49
Quick Ratio	24.99	21.34	17.15
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-35	-60	-73
Operating Cash Flow to CapEx	-47,838.46%	-273,780.00%	-24,988.31%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-5.22	-3.41	-8.87
Invested Capital Turnover	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-2.02	1.81	-5.46
Enterprise Value (EV)	88	80	269
Market Capitalization	218	231	502
Book Value per Share	$7.42	$4.07	$3.97
Tangible Book Value per Share	$7.42	$4.07	$3.97
Total Capital	221	243	319
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-226	-247	-328
Capital Expenditures (CapEx)	0.09	0.03	0.33
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-7.81	-7.14	-13
Debt-free Net Working Capital (DFNWC)	219	239	316
Net Working Capital (NWC)	219	239	316
Net Nonoperating Expense (NNE)	14	15	16
Net Nonoperating Obligations (NNO)	-226	-247	-328
Total Depreciation and Amortization (D&A)	0.00	-0.09	-5.61
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($3.55)	($2.42)	($1.68)
Adjusted Weighted Average Basic Shares Outstanding	14.62M	30.12M	56.16M
Adjusted Diluted Earnings per Share	($3.55)	($2.42)	($1.68)
Adjusted Weighted Average Diluted Shares Outstanding	14.62M	30.12M	56.16M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	27.99M	54.90M	56.43M
Normalized Net Operating Profit after Tax (NOPAT)	-37	-58	-78
Normalized NOPAT Margin	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Astria Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-57.27%	100.00%	12.15%	0.00%	-125.78%	0.00%	-157.82%	-90.58%	-51.95%	9.49%
EBIT Growth	-57.27%	100.00%	12.15%	0.00%	-62.89%	0.00%	-157.82%	-90.58%	-43.43%	13.52%
NOPAT Growth	-56.82%	100.00%	12.26%	0.00%	-126.76%	0.00%	-157.96%	-90.72%	-43.38%	13.47%
Net Income Growth	-52.42%	0.00%	26.99%	0.00%	-47.76%	0.00%	-156.24%	-92.36%	-38.40%	18.41%
EPS Growth	-42.62%	0.00%	66.10%	0.00%	27.59%	0.00%	10.00%	4.44%	33.33%	52.13%
Operating Cash Flow Growth	-32.26%	0.00%	-5.53%	0.00%	-39.12%	0.00%	-88.15%	-56.98%	-96.14%	42.58%
Free Cash Flow Firm Growth	18.20%	126.22%	28.42%	0.00%	-114.22%	-1,372.05%	-57.45%	0.00%	-62.57%	40.73%
Invested Capital Growth	-174.41%	-63.31%	37.12%	0.00%	-33.96%	34.61%	-10.37%	-198.36%	39.24%	-159.78%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-8.46%	100.00%	0.00%	-23.88%	-33.94%	-68.89%	29.34%	-19.24%	-6.79%	-0.60%
EBIT Q/Q Growth	-8.46%	100.00%	0.00%	-23.88%	-33.94%	-137.78%	58.69%	-19.24%	-0.81%	-1.82%
NOPAT Q/Q Growth	-8.18%	100.00%	0.00%	-23.85%	-67.99%	-69.00%	29.38%	-19.27%	-0.73%	-1.99%
Net Income Q/Q Growth	-6.64%	0.00%	0.00%	-12.32%	-41.07%	-154.37%	36.56%	-42.59%	-1.50%	-4.45%
EPS Q/Q Growth	-1.16%	0.00%	0.00%	-25.00%	-80.00%	-49.21%	59.57%	-26.32%	2.33%	-7.14%
Operating Cash Flow Q/Q Growth	-1.87%	0.00%	0.00%	38.59%	-33.30%	-224.15%	73.71%	12.06%	-66.55%	37.92%
Free Cash Flow Firm Q/Q Growth	16.59%	132.03%	0.00%	200.00%	0.00%	-90.19%	0.00%	19.27%	-45.82%	30.67%
Invested Capital Q/Q Growth	-20.92%	-41.15%	0.00%	-59.76%	-69.29%	42.20%	36.38%	-502.21%	65.53%	-237.35%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	0.00%	100.00%	200.00%	100.00%	100.00%	200.00%	100.00%	100.00%	100.00%
Interest Burden Percent	96.49%	0.00%	82.82%	166.20%	87.52%	183.65%	82.45%	167.75%	84.45%	86.63%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-39.51%	-30.18%	0.00%	0.00%	-36.82%	-31.40%	-56.39%	-34.06%	-38.03%	-33.52%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-8.20%	-13.24%	0.00%	0.00%	-13.08%	-36.87%	-37.82%	-22.20%	-24.25%	-22.16%
Return on Equity Simple (ROE_SIMPLE)	-42.58%	0.00%	0.00%	0.00%	-29.68%	0.00%	-44.40%	-26.86%	-29.28%	0.00%
Net Operating Profit after Tax (NOPAT)	-8.67	0.00	-9.45	-11	-14	-24	-17	-20	-20	-21
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-2.68%	0.00%	-1.07%	-1.97%	-2.33%	-6.19%	-2.07%	-1.44%	-1.58%	-1.71%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-9.85%	-	-	-	-6.49%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-12	0.00	-14	-15	-20	-34	-24	-29	-29	-30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-12	0.00	-14	-15	-20	-34	-24	-29	-31	-31
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.54	1.74	3.20	2.22	2.35	1.57	5.40	2.04	2.58	2.24
Price to Tangible Book Value (P/TBV)	7.54	1.74	3.20	2.22	2.35	1.57	5.40	2.04	2.58	2.24
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.02	-1.02	-1.02	-2.03	-1.03	-1.02	-1.01	-1.02	-1.01	-1.02
Leverage Ratio	1.05	1.04	1.04	1.04	1.05	1.05	2.06	2.10	1.06	1.06
Compound Leverage Factor	1.01	0.00	0.86	0.87	1.85	1.92	1.70	0.88	0.89	0.92
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	85.40%	43.58%	45.10%	95.13%	103.34%	39.21%	51.84%	54.93%	27.90%	29.86%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	14.60%	56.42%	54.90%	104.87%	96.66%	121.58%	148.16%	145.07%	72.10%	70.14%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	5.74	11.93	30.03	18.37	10.19	19.02	77.22	13.23	17.45	11.10
Noncontrolling Interest Sharing Ratio	79.24%	56.12%	59.72%	127.89%	128.95%	41.29%	65.84%	34.82%	36.24%	33.90%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	18.40	25.13	32.29	30.98	40.82	43.45	67.65	21.87	22.38	17.49
Quick Ratio	18.10	24.99	31.97	61.52	20.12	42.69	33.41	43.34	21.90	17.15
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-6.32	2.02	-11	0.00	-14	-26	-17	-15	-22	-15
Operating Cash Flow to CapEx	-17,670.69%	0.00%	-265,060.00%	0.00%	-712,900.00%	-377,975.00%	0.00%	-5,505.25%	-139,825.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-3.70	-5.22	-1.97	-2.56	-4.33	-3.41	-2.17	-7.63	-2.63	-8.87
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-2.35	-2.02	1.16	0.00	-0.63	1.81	-0.20	-5.07	1.70	-5.46
Enterprise Value (EV)	104	88	254	126	116	80	461	255	388	269
Market Capitalization	124	218	372	233	209	231	736	514	637	502
Book Value per Share	$1.27	$7.42	$4.15	$3.75	$3.18	$4.07	$5.21	$4.58	$4.37	$3.97
Tangible Book Value per Share	$1.27	$7.42	$4.15	$3.75	$3.18	$4.07	$5.21	$4.58	$4.37	$3.97
Total Capital	113	221	211	200	184	243	368	347	342	319
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-117	-226	-213	-203	-189	-247	-370	-355	-344	-328
Capital Expenditures (CapEx)	0.06	0.00	0.01	0.00	0.00	0.02	0.00	0.31	0.02	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-4.53	-7.81	-4.56	-5.14	-6.72	-7.14	-6.46	-13	-8.14	-13
Debt-free Net Working Capital (DFNWC)	112	219	209	198	182	239	363	342	336	316
Net Working Capital (NWC)	112	219	209	198	182	239	363	342	336	316
Net Nonoperating Expense (NNE)	3.33	0.00	1.74	1.99	3.56	7.47	3.02	4.01	4.22	4.91
Net Nonoperating Obligations (NNO)	-117	-226	-213	-203	-189	-247	-370	-355	-344	-328
Total Depreciation and Amortization (D&A)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.73	-1.38
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.87)	$0.00	($0.40)	($0.45)	($0.63)	($0.94)	($0.38)	($0.43)	($0.42)	($0.45)
Adjusted Weighted Average Basic Shares Outstanding	13.74M	14.62M	27.94M	28.02M	28.04M	30.12M	52.29M	56.49M	57.82M	56.16M
Adjusted Diluted Earnings per Share	($0.87)	$0.00	($0.40)	($0.45)	($0.63)	($0.94)	($0.38)	($0.43)	($0.42)	($0.45)
Adjusted Weighted Average Diluted Shares Outstanding	13.74M	14.62M	27.94M	28.02M	28.04M	30.12M	52.29M	56.49M	57.82M	56.16M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	16.83M	27.99M	28.03M	28.04M	36.30M	54.90M	54.91M	112.85M	56.43M	56.43M
Normalized Net Operating Profit after Tax (NOPAT)	-8.67	0.00	-9.45	-11	-14	-24	-17	-20	-20	-21
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Astria Therapeutics' Financials

When does Astria Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Astria Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Astria Therapeutics' net income changed over the last 2 years?

Astria Therapeutics' net income appears to be on an upward trend, with a most recent value of -$94.26 million in 2024, rising from -$51.83 million in 2022. The previous period was -$72.89 million in 2023. See Astria Therapeutics' forecast for analyst expectations on what’s next for the company.

What is Astria Therapeutics's operating income?

Astria Therapeutics's total operating income in 2024 was -$111.56 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $111.56 million

How has Astria Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Astria Therapeutics' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Astria Therapeutics have?

Astria Therapeutics' total liabilities were at $23.10 million at the end of 2024, a 100.0% increase from 2023, and a 145.3% increase since 2022.

How much cash does Astria Therapeutics have?

In the past 2 years, Astria Therapeutics' cash and equivalents has ranged from $20.53 million in 2022 to $175.53 million in 2023, and is currently $59.82 million as of their latest financial filing in 2024.

How has Astria Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Astria Therapeutics' book value per share changed from 7.42 in 2022 to 3.97 in 2024, a change of -46.5%.

Related Companies

This page (NASDAQ:ATXS) was last updated on 5/4/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Astria Therapeutics (ATXS) Financials

Frequently Asked Questions About Astria Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Astria Therapeutics (ATXS) Financials

Annual Income Statements for Astria Therapeutics

Quarterly Income Statements for Astria Therapeutics

Annual Cash Flow Statements for Astria Therapeutics

Quarterly Cash Flow Statements for Astria Therapeutics

Annual Balance Sheets for Astria Therapeutics

Quarterly Balance Sheets for Astria Therapeutics

Annual Metrics and Ratios for Astria Therapeutics

Quarterly Metrics and Ratios for Astria Therapeutics

Frequently Asked Questions About Astria Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools